DR. WAI KIT   MA (Orcid ID : 0000-0002-5523-9735)

Article type   : Review

Title:

Consensus statements on the management of clinically localised prostate cancer from the Hong Kong

Urological Association and the Hong Kong Society of Uro-Oncology

Authors:

Wai-Kit (WK) MA[a], Darren Ming-Chun (MC) POON[b], Chi-Kwok (CK) CHAN[c], Tim-Wai (TW)

CHAN[d], Foon-Yiu (FY) CHEUNG[e], Lap-Yin (LY) HO[f], Eric Ka-Chai (KC) LEE[g], Angus

Kwong-Chuen (KC) LEUNG[h], Simon Yiu-Lam (YL) LEUNG[i], Hing-Shing (HS) SO[j], Po-Chor (PC)

TAM[k], Philip Wai-Kay (WK) KWONG[l]

Institutions and contacts:

[a] Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong. Email:

kitkitma@yahoo.com

[b] Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao

Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University

of Hong Kong, Hong Kong. Email: mc_poon@clo.cuhk.edu.hk

[c] Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of

Hong Kong, Hong Kong. Email: chanck@surgery.cuhk.edu.hk

[d] Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong. Email: ctw263@ha.org.hk

[e] Hong Kong Integrated Oncology Centre, Hong Kong. Email: cheungfy@gmail.com

[f] Asia Clinic, Hong Kong. Email: holapyin@yahoo.com.hk

[g] Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong. Email:

leekachai2000@yahoo.com.hk

[h] AMO Oncology Centre, Hong Kong. Email: anguskcleung@gmail.com

[i] Central Urology Clinic, Hong Kong. Email: sleung@centralurology.com.hk

j Division of Urology, Department of Surgery, United Christian Hospital, Hong Kong. Email:

atticushsso@yahoo.com.hk

k Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong. Email:

dr.pctam@gmail.com

l Department of Clinical Oncology, The University of Hong Kong, Queen Mary Hospital, Hong Kong.

Email: pwkkwong@ha.org.hk

Corresponding author:

Wai-Kit MA

Mailing address: Department of Surgery, The University of Hong Kong, 2/F, Professorial Block,

Queen Mary Hospital, 102 Pokfulam Road, Hong Kong.

Email: kitkitma@yahoo.com

Article Category: Review

Abstract:

To formulate consensus statements to facilitate physician management strategies for patients with clinically localised prostate cancer (PCa) in Hong Kong, a panel of 12 experts who previously established consensus statements on the management of metastatic PCa for the locality was convened jointly by the two local professional organisations representing prostate cancer specialists. Through a series of meetings, the panellists discussed their clinical experience and the published evidence regarding various areas of the management of localised PCa, followed by the drafting of consensus statements. At the final meeting, each drafted statement was voted upon by every panellist based on its practicability of recommendation in the locality. A total of 76 consensus statements were ultimately accepted and established by panel voting. Derived from the recent evidence and major overseas guidelines, along with local clinical experience and practicability, the consensus statements are aimed to serve as a practical reference for physicians in Hong Kong for the management of localised PCa.

Introduction

In Hong Kong, the incidence of prostate cancer (PCa) has been on a steady rise over the past several decades [1]. It is a common cancer and a significant cause of death in the male population of the city [2]. In recent years, there have been a number of controversies over the management of localised PCa

[3,4]. To optimise the diagnostic and treatment approaches to localised PCa in Hong Kong, a local expert panel co-organised by the Hong Kong Urological Association (HKUA) and the Hong Kong Society of Uro-Oncology (HKSUO), which previously established consensus statements on the management of metastatic PCa for the territory [5], was re-convened to formulate consensus statements on the management of localised PCa, based on recent clinical evidence and the panellists' insights.

Method

The panellists were listed by affiliation and specialty in a previous consensus publication [5]. They discussed the following seven major areas regarding the management of localised PCa: (1) diagnostic work-up recommended for men with suspicious clinically localised PCa; (2) diagnostic work-up for patients with localised PCa confirmed by biopsy; (3) parameters for treatment decisions for localised PCa; (4) risk stratification of newly diagnosed localised PCa; (5) treatment approaches to localised PCa; (6) follow-up and monitoring after definitive local treatment; and (7) management of *de novo* pelvic nodal disease (with evidence of pelvic lymph node metastasis on presentation, but M0).

The relevant literature was searched on the PubMed database using the following keywords: active surveillance; androgen deprivation; AR signalling pathway inhibitors; biomarker; biopsy; bone scan; chemotherapy; focal therapy; guideline; localised prostate cancer; magnetic resonance imaging; pelvic dissection; pelvic floor muscle training; pelvic nodal disease; penile rehabilitation; positron emission tomography; progression; radical prostatectomy; radiotherapy; recurrence; risk stratification; surgery; watchful waiting; and work-up [evaluation]. Only articles published between January 2005 and June 2017 were included for review.

Using a modified Delphi method [6] (Appendix S1), a series of panel meetings were held for discussions on clinical experience and available evidence, for the ultimate purpose of developing consensus statements. Based on the approach previously used to generate consensus statements [5], every panellist voted on each statement anonymously at the final meeting. A consensus statement was accepted only if ≥ 80% of the panellists chose 'accept completely' or 'accept with some reservation'. Full voting results for each drafted statement are included in Appendix S2.

Results

A total of 76 consensus statements were accepted and established by panel voting.

Part 1: Diagnostic work-up recommended for men with suspicious clinically localised PCa

Statement 1: 'For men with prostate-specific antigen (PSA) = 4 to 10 ng/mL (not caused by infections or urethral manipulation), a biopsy should be considered to confirm PCa, in particular among those with symptoms, an abnormal digital rectal examination (DRE) result, or relevant family history. Before a biopsy is done, a free/total PSA ratio (f/t PSA) or a prostate health index (PHI) can be considered to aid the counselling process.'

Based on a number of large screening studies, normal PSA levels have been defined as ≤ 4 ng/mL [7]. Men with PSA levels of 4–10 ng/mL have a 22–27% chance of developing PCa, while those with PSA levels > 10 ng/mL have a 67% chance [7]. Therefore, in men with PSA levels of 4–10 ng/mL, it is reasonable to conduct a biopsy to diagnose PCa, given that non-cancer-related causes of elevated PSA levels, such as prostatitis and urethral manipulation, have been ruled out. In particular, those with clinically suspicious symptoms of PCa or relevant family history, in addition to elevated PSA levels, should undergo a biopsy. In cases of an abnormal DRE, a follow-up biopsy should be done, regardless of the PSA level [8].

To reduce unnecessary biopsies, a f/t PSA or a PHI can be used to assist in the clinical judgement and counselling process. In a report by Catalona et al [9], a lower f/t PSA was associated with a higher risk of PCa, which ranged from 8% (f/t PSA > 25%) to 56% (f/t PSA ≤ 10%), in men with PSA levels of 4–10 ng/mL. Hence, f/t PSA ≤ 25% can act as a cut-off point for biopsy decision-making. Regarding PHI, Ng et al [10] found that, among Asian men with PSA levels of 4–10 ng/mL, a cut-off of PHI > 26.54 for performing a biopsy yielded a specificity of 49.76% (95% confidence interval [CI]: 42.8–56.7; sensitivity, 90%) in the detection of PCa.

Statement 2: 'To detect PCa in biopsy-naïve men, a transrectal ultrasound (TRUS)-guided systematic biopsy (10 to 12 cores) is recommended.'

Based on several systematic reviews [11-13], in the initial biopsy setting for overall PCa detection, targeted biopsies have no clear advantage over systematic biopsies. A similar result was found in a prospective study conducted in Hong Kong [14]. Meanwhile, there is emerging evidence that suggests the use of multiparametric magnetic resonance imaging (mpMRI) as a triage test before first prostate biopsy. The PROMIS study [15] showed that using mpMRI could reduce unnecessary primary biopsies by 27% and the diagnosis of clinically insignificant cancers by 5%. Subsequent TRUS-biopsies guided by mpMRI could detect up to 18% more cases of clinically significant cancer

compared with the standard pathway of TRUS-biopsy. In the updated guideline of the National Institute for Health and Care Excellence (NICE) in the UK [16], which is in development and due to be published in April 2019, mpMRI is recommended as the first-line investigation for men with suspected clinically localised PCa, and mpMRI-guided prostate biopsy should be offered to men with a Likert score ≥ 3.

The use of mpMRI and mpMRI-guided biopsy in the first-line setting is currently debatable, as the practice has not been consistently recommended across the literature or various guidelines. The local clinical experience using mpMRI in the biopsy-naïve setting is limited. In addition, the Likert score, suggested by NICE as a measure for performing mpMRI-guided biopsy [16], is a relatively new criterion, and one that has not been generally recognised among local physicians. Although there is increasing evidence on the role of mpMRI and fusion biopsy in improving the detection of localised PCa, their use in the first-line setting remains investigational in the locality, until more data and experience are gained. In view of current local clinical experience, a TRUS-guided systematic 10–12 core biopsy remains the standard scheme for the diagnosis of PCa.

Statement 3: 'To detect PCa in a repeat biopsy setting, mpMRI or the combination of systematic and MRI-targeted biopsies (either with cognitive guidance or mpMRI/ultrasound fusion) can be offered.'

In a Hong Kong study [14], mpMRI showed a promising specificity for negative imaging, with no PCa detected on systematic biopsy of 11 MRI-negative patients, and the combination of systematic (12-core) and mpMRI/TRUS fusion-guided biopsies yielded a significantly higher overall cancer detection rate compared with a systematic biopsy (33.3% vs 17.6%, P = 0.01). Due to its high specificity, mpMRI has been recommended by clinical guidelines to confirm the diagnosis of PCa when initial biopsy results are negative [17]. With higher PCa detection rates [13], the combination of systematic and MRI-targeted biopsies is preferred to systematic biopsies alone in the repeat biopsy setting, while the targeted biopsy involved can be guided by either cognitive registration or mpMRI/TRUS fusion, because there is no significant difference in overall PCa detection rates between these two means of guidance [12]. Thus, mpMRI or the combination of systematic and MRI-targeted biopsies can be used to confirm the diagnosis of PCa in the repeat biopsy setting.

Part 2: Diagnostic work-up for patients with localised PCa confirmed by biopsy

Statement 1: 'In cases of a PSA ≤ 20 ng/mL, Gleason score ≤ 3+4, ISUP grade ≥ 2, or tumour size ≥ T2b, mpMRI should be performed to check for the presence of extracapsular extension (ECE) and pelvic status before curative treatment planning.'

Despite its low sensitivity (~58%), mpMRI is the optimal imaging tool due to its high specificity (~90%) for the detection of ECE in localised PCa [18,19], which is a poor prognostic factor associated with disease progression and decreased overall and PCa-specific survival after radical prostatectomy (RP) [20,21]. The high specificity of mpMRI can help reduce the unnecessary exclusion of patients from curative surgery [18,19].

Statement 2: 'In cases of a PSA > 20 ng/mL or Gleason score ≥ 4+3, further imaging should be performed for metastatic staging. Whole-body prostate-specific membrane antigen (PSMA) PET-CT scan is preferred if resources or facilities are available. Otherwise, pelvic MRI plus bone scan is an acceptable option.'

Considering the high risk of metastatic spread in patients with PSA levels > 20 ng/mL or a Gleason score ≥ 4+3, identification of metastases is crucial for determining treatment approaches. The use of positron emission tomography (PET) using PSMA ligands for the detection of metastatic disease in vulnerable patients with localised PCa has been increasing. PSMA PET (using ^{68}Ga-PSMA in most studies) combined with computed tomography (CT) have superior sensitivity and specificity in the detection of bone and nodal involvement compared with bone scan, MRI, CT and PET-CT using other tracers [22-24]. Therefore, whole-body PSMA PET-CT is a preferable imaging tool for metastatic staging in susceptible patients, although more prospective studies are warranted to evaluate the effect of the modality on treatment outcomes.

Considering cost and facility issues in some local healthcare institutions, the combination of pelvic MRI and bone scan is an acceptable alternative for metastatic staging in patients with PSA levels > 20 ng/mL or a Gleason score ≥ 4+3 [25,26].

Part 3: Parameters for treatment decisions for localised PCa

Statement 1: 'Factors important for PCa treatment decision-making include: (a) life expectancy (i.e. < 10 years vs ≥ 10 years); (b) comorbidities; (c) performance status; (d) International Society of Urological Pathology (ISUP) grading; (e) TNM staging; (f) Gleason score; and (g) serum PSA level and PSA velocity.'

Life expectancy

Nowadays, men diagnosed with early-stage PCa are expected to live for a significant period possibly because of the healthy screener effect [27]. In a USA population-based study [28], patients diagnosed with loco-regional PCa had higher non-cancer survival rates than the general population. Similarly, a Swedish population-based study [29] found that, compared with PCa-free subjects, men with low-risk PCa had reduced 10-year all-cause mortality, while patients with intermediate- and high-risk PCa had increased all-cause mortality, with PCa as the most common death cause among them. Many men with PCa have a life expectancy higher than expected compared with their age- and race-matched counterparts [27]. The life expectancy of individuals with PCa should be assessed carefully based on age and comorbidity when deciding on an optimal management approach.

Comorbidities

In population-based studies [29,30], men with localised PCa and a higher Charlson comorbidity index (CCI) score (≥ 2) were generally associated with a higher overall mortality and lower PCa-specific mortality, because they had a significant risk of death due to a competing medical hazard other than PCa. Comorbidities are worth considering to prevent overtreatment in men with localised PCa who are more threatened by non-PCa health risks [31].

Performance status

Similar to comorbidities, poor performance status may pose additional threats to men with localised

PCa, so it is deemed relevant to guide treatment strategies between surgery, radiation and palliative

hormonal therapy.

ISUP grading

The grading system of PCa established by the ISUP (Table 1) [32] has been increasingly adopted by

different countries. The prognostic effect of the five grading categories has been validated in a large

multi-institutional study of > 20,000 RP cases and > 5,000 radiotherapy (RT) cases [33]. Compared

with the Gleason score, the ISUP grading simplifies the classification of PCa, with the lowest grade

being 1, as opposed to 6, which may help reduce overtreatment of PCa [33]. The ISUP grading has

been accepted by the World Health Organization for the classification of prostate tumours [34]. The

grading system is worthy of use for the pathological assessment of PCa in Hong Kong.

TNM staging

The TNM staging is a major component in the risk stratification of PCa, and thus crucial in guiding treatment decisions. Tumour volume has been shown to be independently correlated with PSA recurrence in men undergoing RP for localised PCa [35]. Hence, it, along with other clinical variables, may serve as a prognostic factor of outcomes of RP.

Gleason score

The Gleason score plays a crucial role in stratifying the risk of localised PCa and is also the basis of the ISUP grading system. A high Gleason score (9–10) has been shown to be associated with poor survival outcomes in patients treated with RP or RT for localised PCa [36,37].

Serum PSA and PSA velocity

PSA and its derivatives have been shown to be prognostic factors of treatment outcomes in patients with localised PCa. In a retrospective cohort study of men treated with RT for localised PCa [38], a PSA velocity > 2.0 ng/mL versus ≤ 2.0 ng/mL during the year before diagnosis was associated with a significantly higher risk of PCa-specific death (adjusted hazard ratio [HR] 12.0, 95% CI 3.0–54.0; P = 0.001), suggesting that androgen deprivation therapy (ADT) in addition to RT may be considered in

men with a higher PSA velocity and with higher-risk disease to improve survival. A prospective study [39] found that PSA density (serum PSA level ÷ prostate volume) was a significant determinant of PSA velocity in untreated, localised PCa, and that patients with low-risk PCa but with a high PSA density (≥ 0.15 ng/mL/mL) might be more likely to benefit from immediate radical treatment rather than active surveillance.

Part 4: Risk stratification of newly diagnosed localised PCa

Statement 1: 'The D'Amico risk stratification of localised PCa is the basis of the subsequent statements on treatment strategies, as it was adopted in most of the published research.'

The D'Amico risk stratification [40] is a well-established system to stratify patients with localised PCa into three risk groups (Table 2), which facilitates decision-making on treatment approaches and has been widely used in the currently available literature. It has been a reference for the management of localised PCa in most cancer centres in Hong Kong. Therefore, the D'Amico risk stratification of localised PCa is adopted as the basis of the subsequent statements on treatment strategies.

Statement 2: 'It is acknowledged that the European Association of Urology (EAU) and the National Comprehensive Cancer Network (NCCN) released their updated risk stratifications in 2017, which allow for more individualised classification of patients compared with the D'Amico risk stratification; however, the subsequent consensus statements on treatment strategies are still generally applicable when referring to these updated risk stratification systems.'

The EAU and the NCCN in the USA released their respective latest guidelines on the management of localised PCa in 2017 [17,41], which include more individualised classification of patients compared with the D'Amico risk stratification. Although the consensus statements to follow on treatment strategies are primarily based on the D'Amico risk stratification, they are still generally applicable when following the 2017 guidelines. Indeed, some recommendations that were suggested recently by the EAU and the NCCN have been incorporated into the following consensus statements where applicable.

Part 5: Treatment approaches to localised PCa

5.1: Watchful waiting

Statement 1: **'**Watchful waiting should be offered to patients not eligible for local curative treatment (e.g. poor premorbid status) and those with a short life expectancy (< 10 years), irrespective of the risk group.'

The statement was mainly based on two randomised studies conducted in men with early PCa [42,43]. In the SPCG-4 trial [42], after 23.2 years of follow-up, compared with watchful waiting, RP was associated with significant reductions in all-cause mortality, cancer-specific mortality, and the risk of metastases among men with intermediate-risk PCa (absolute difference: 15.5, 24.2, and 19.9 percentage points, respectively). Among the low-risk group, although RP was associated with significant reductions in all-cause mortality and the risk of metastases (absolute difference: 15.6 and 10.6 percentage points, respectively), no significant reduction in cancer-specific mortality was observed (absolute difference: 3.8 percentage points). In men with high-risk PCa, there was no significant reduction in any of the three primary endpoints among those treated with RP. The PIVOT trial [43] found that, after 19.5 years of follow-up, RP was associated with lower all-cause mortality than observation among men with intermediate-risk PCa (absolute difference: 14.5 percentage points),

but not among those with low-risk or high-risk disease (absolute difference: 0.7 and 2.3 percentage points, respectively).

The comparable results of the two trials imply that, owing to its survival benefits, RP, rather than watchful waiting, is particularly favourable for men with intermediate-risk disease who have long life expectancies. In contrast, RP may have no significant survival benefits compared with observation among men with low-risk PCa; therefore, watchful waiting may be considered before early use of radical treatment. The approach is also worth considering in men with high-risk PCa, especially those with a poor prognosis and a short life expectancy, because RP may not benefit them. In short, watchful waiting can be an option for all patients with PCa who are ineligible for local curative treatment.

5.2: Active surveillance

Statement 1: 'Active surveillance is an option for patients with a life expectancy of > 10 years and low-risk PCa, i.e. biopsy Gleason score 6, ≤ 2 positive biopsies, minimal biopsy core involvement (≤ 50% cancer per biopsy), PSA ≤ 10 ng/mL, and cT1–2.'

A number of prospective series [44] showed positive overall and disease-specific survival rates (70–90%) among men with low-risk PCa treated with active surveillance. Most of the studies, however, had a relatively short follow-up (5–10 years). In a more mature series [45], among men receiving active surveillance (25% with intermediate-risk PCa), the 10- and 15-year overall survival (OS) rates were 80% and 62%, respectively; the 10- and 15-year actuarial cause-specific survival rates were 98.1% and 94.3%, respectively. Another large cohort study [46] showed that overall, cancer-specific, and metastasis-free survival rates among men with low-risk PCa under active surveillance were 93%, 99.9%, and 99.4%, respectively, at 10 years and 69%, 99.9%, and 99.4%, respectively, at 15 years. In the ProtecT randomised trial [47], among 2,664 patients with localised PCa, the number of PCa-specific deaths at a median follow-up of 10 years was low, regardless of the treatment assigned (8, 5, and 4 in the active-surveillance, surgery, and RT groups, respectively), with no significant difference between the groups; however, compared with active surveillance, surgery and RT were associated with lower incidences of disease progression and metastases.

Based on the above evidence, together with the EAU guidelines [17], active surveillance is an option for men with low-risk PCa who have a life expectancy of > 10 years. Although there is no standard protocol for active surveillance across different international guidelines [48], regular PSA testing and biopsies are widely adopted. If active surveillance is chosen, physicians should ensure the patient's

compliance to the follow-up protocol and counsel him about the potential need for further treatment in the future.

5.3: Focal therapy

Statement 1: 'Focal therapy is not recommended in patients with localised PCa, regardless of the risk category, except in a clinical trial setting.'

In a systematic review [49], the rates of disease recurrence in patients with PCa treated with cryotherapy and those treated with high-intensity focused ultrasound were 13.2–26% and 7.3–67.9%, respectively. At 12 months, > 95% and > 85% of patients demonstrated continence and sexual potency, respectively, regardless of the type of focal therapy used. Despite the positive outcomes, the clinical usage of focal therapy for PCa remains controversial [50]. The main limitation of the treatment modality is the difficulty in localising the lesions in most cases; therefore, it is not recommended as a standard treatment for PCa.

5.4: Surgery

5.4.1: Radical prostatectomy (RP)

Statement 1: 'RP should be a treatment option for patients with localised PCa, regardless of the

risk category.'

RP is a standard treatment option for localised PCa, based on the survival benefits compared with

watchful waiting as shown in the randomised controlled trial SPCG-4 [51,52].

Statement 2: 'RP approaches can be robot-assisted laparoscopic, pure laparoscopic, open

retropubic, or perineal, depending on the patient's and the surgeon's preference.'

In a systematic review that analysed two randomised trials [53], although there was no high-quality

evidence to show the comparative oncological outcomes of laparoscopic radical prostatectomy (LRP)

or robot-assisted radical prostatectomy (RARP) compared with open radical prostatectomy (ORP) in

the treatment of PCa, all of the surgical approaches were found to have similar urinary and sexual

quality of life-related outcomes. In comparison with ORP, LRP or RARP may be associated with a

reduced hospital stay and fewer blood transfusions. In a retrospective analysis conducted in Hong Kong [54], there was no significant difference in early oncological outcomes between RARP and ORP, while RARP may lead to less blood loss and a shorter hospital stay than ORP, consistent with the conclusions of the systematic review.

A study done at a Chinese medical centre [55] found that, among patients with PCa who were treated with RARP, postoperative continence at 1 year and 6 months was better in those treated by the surgeons with previous LRP experience compared with those treated by a surgeon with prior ORP experience only. This implies that previous LRP experience may improve the learning curve of RARP.

Because current evidence does not show a significant difference in functional outcomes between different surgical techniques, surgeons are expected to select an approach based on their own preference, experience and patients' acceptance.

5.4.2: Nerve-sparing surgery

Statement 1: 'Nerve-sparing surgery should be offered to patients with a low risk of extracapsular disease (based on nomograms), regardless of the PCa risk category.'

According to the EAU guidelines [17], nerve-sparing surgery is recommended in patients with localised PCa who have a low risk of extracapsular disease. The practice has been adopted by local urologists in general. To assess the risk of extracapsular disease, physicians should consider the patient's baseline erectile functionand the location and extent of the tumour with reference to nomograms.

5.4.3: Pelvic lymph node dissection (PLND)

Statement 1: 'PLND is the gold standard for nodal staging in the detection of lymph node invasion (LNI) in localised PCa.'

Conventional imaging tools, such as CT and MRI, are unable to predict LNI in PCa [56,57], while the usage of emerging techniques, such as PET-CT scans, remains investigational in this field. Therefore, a PLND is currently the most reliable staging method for the detection of LNI in PCa.

Statement 2: 'Standard PLND includes removal of obturator nodes, with or without removal of external iliac nodes.'

Statement 3: 'Extended PLND (ePLND) includes the removal of obturator, external iliac and hypogastric nodes, with or without the removal of presacral and common iliac nodes.'

When carrying out a PLND, surgeons must decide on the extent based on the clinical needs of patients. A standard, or limited, PLND is restricted to the removal of obturator nodes, with the removal of external iliac nodes in some circumstances. The definition of an ePLND varies in the literature, but in general, it should involve the removal of lymph nodes along the hypogastric artery [56]. Based on clinical practices, an ePLND should involve the removal of obturator, external iliac and hypogastric nodes, irrespective of the removal of presacral and common iliac nodes.

An ePLND is significantly more accurate in the detection of lymph node metastasis compared with a standard PLND, which is often associated with a bias towards low rates of LNI due to insufficient nodal sampling [56,57]. Hence, an ePLND is preferable to a standard PLND for nodal staging. Of note, although an ePLND is not associated with a significant risk of serious complications, up to 10% of the patients undergoing this procedure experience lymphoceles [57].

Statement 4: 'PLND is not recommended in patients with low-risk PCa.'

The overall LNI rate is not significant in patients with low-risk PCa [56]. Several overseas guidelines [17,41,58] do not strongly recommend a staging PLND in this group of patients. Considering the benefit-risk balance, a PLND at the time of RP is not recommended in men with low-risk PCa.

Statement 5: 'In patients with intermediate-risk PCa, an ePLND should be performed when the estimated risk of lymph node metastasis is > 5% based on nomograms.'

Statement 6: 'An ePLND should be performed in all patients with high-risk PCa.'

International guidelines [17,41,58] generally recommend a PLND performed at the time of RP in patients with intermediate-risk PCa at significant risk of lymph node metastasis. The EAU recommendation, as described in the consensus statement, is applicable in the locality. For men with high-risk PCa, the international guidelines share a common recommendation that all of these patients should undergo a PLND at the time of RP. The panel generally agreed on the practice and highlighted the use of an ePLND, instead of a standard PLND.

Despite the importance of a PLND for nodal staging, a retrospective review of the pathology of > 1,000 PLNDs (extended or standard) [59] showed that, at a median follow-up of 4 years, only 10% of men with a positive lymph node metastasis remained free of biochemical recurrence of disease, and only 5% had undetectable serum PSA. The number of men needed to be treated (NNT) with a PLND to reach an undetectable post-RP PSA is ~400. In view of the low probability of being biochemically free of recurrent disease and the high NNT for cure in men with lymph node metastasis, more research is warranted to identify the individuals who will benefit from a PLND, possibly with the use of emerging radiological imaging tools.

5.4.4: Post-surgery care

Statement 1: 'The effectiveness of pelvic floor muscle training in improving urinary incontinence after surgery remains uncertain based on current literature; however, in view of its non-invasiveness, the behavioural exercise can still be considered to help with the recovery of continence function.'

As per two meta-analyses [60,61], neither pre- nor post-operative pelvic floor exercises offer a significant improvement in urinary incontinence. Nevertheless, the included studies had considerable variation in interventions, populations and outcome measures. More robust evidence from randomised

controlled trials is required to further analyse the effect of pelvic floor exercises. Despite mixed evidence to date, pelvic floor exercises are still worth considering in patients who plan to undergo RP, because they are non-invasive and may potentially help improve continence function.

Statement 2: 'Penile rehabilitation with a daily low-dose phosphodiesterase 5 inhibitor (PDE5i) should be offered to patients as soon as possible after surgery.'

In a trial that randomised patients who had undergone nerve-sparing RP to tadalafil 5 mg once daily, 20 mg on demand or placebo [62], at the end of the double-blind period (9 months), only those treated with tadalafil 5 mg once daily had a statistically significant improvement in erectile function compared with the placebo group. A sub-analysis of the study [62] also found that tadalafil 5 mg once daily was associated with a significantly reduced time to erectile function recovery during the 9-month treatment. Although its long-term efficacy needs to be further explored [63], the early prescription of a daily low-dose PDE5i is feasible to facilitate penile rehabilitation in patients who have undergone RP.

5.5: Radiotherapy (RT)

5.5.1: External beam RT (EBRT)

Statement 1: 'EBRT should be a treatment option for patients with localised PCa, regardless of the risk category.'

Statement 2: 'Intensity-modulated RT (IMRT) is recommended as the standard of care for dose-escalated RT in all risk groups of localised PCa.'

EBRT is a recognised principal treatment option for localised PCa, and multiple phase III randomised controlled trials [64-67] have shown that dose escalation (78 Gy vs 70 Gy) can improve biochemical control in patients with localised PCa from all risk groups. Compared with the conventional three-dimensional conformal RT (3D-CRT), IMRT, an advanced form of high-precision radiation that conforms the treatment volume to the prostate, is a safer approach to dose escalation and can spare more normal tissues, especially those in the rectum and bladder, in view of its dosimetry. A number of retrospective studies [68] have shown that IMRT results in similar biochemical control but with fewer acute or late gastrointestinal (GI) or genitourinary (GU) complications compared to 3D-CRT among

men with localised PCa. Despite no randomised trials directly comparing the two approaches, IMRT, instead of 3D-CRT, has become the standard dose-escalated RT for localised PCa [68-70].

In a retrospective study conducted in Hong Kong [71], a substantial proportion of patients with localised PCa achieved biochemical failure-free survival at 5 years after treatment with IMRT (95%, 82%, and 80% for the low-, intermediate-, and high-risk groups, respectively), with grade 2/3 late GI/GU toxicities observed in 3–8% of patients. These results are consistent with the outcomes of IMRT found in western countries, supporting the view that IMRT is effective and safe in local patients. On balance, IMRT is the standard dose-escalated RT for localised PCa, irrespective of the risk category.

Statement 3: 'Moderate hypofractionation (60 Gy/20 fractions in 4 weeks) can be considered as an alternative to conventional IMRT when clinically indicated.'

Radiobiological models suggest that PCa has a low $\alpha{:}\beta$ ratio of ~1.5 Gy, implying that the cancer cells are more sensitive to RT doses delivered in large fraction sizes rather than small ones [72]. A dose of 1.8–2 Gy/fraction is regarded as conventional RT, whereas hypofractionated RT can be classified as moderate (2.4–4.0 Gy/fraction over 4–6 weeks) or extreme hypofractionation (i.e. SBRT, 6–10

Gy/fraction, usually completed within 5 fractions of treatment). Despite no superiority found in the

HYPRO trial [73], moderate hypofractionation (57–70 Gy in 2.5–3.4 Gy/fraction used in the trials)

was similarly safe and effective compared to conventional fractionation in three large randomised

non-inferiority trials [74-76]. Therefore, moderate hypofractionation (60 Gy in 20 fractions over 4

weeks) can serve as an alternative to conventional IMRT in the treatment of localised PCa when

clinically indicated.

Statement 4: 'Stereotactic body RT (SBRT) can be considered as an alternative to conventional

IMRT at centres with appropriate facilities and clinical expertise.'

Over the past decade, phase I/II studies [77,78] have found that SBRT, or extreme hypofractionation,

is comparable to conventional fractionation in terms of toxicity and efficacy. Hence, SBRT can be

considered as an alternative to conventional IMRT in the treatment of PCa, given that relevant

facilities and experts are available. Of note, when SBRT is planned, image-guided RT (IGRT) is

required to allow a safe and precise delivery of high-dose RT.

In Hong Kong, a phase II randomised trial comparing conventional IMRT versus SBRT (7.5 Gy × 5 fractions) has recently completed the patient accrual [79]. Apart from the clinical benefits, this ongoing trial will assess whether SBRT has a potential economic advantage and offers more convenience for patients because of its shorter treatment duration compared to conventional IMRT.

> Statement 5: 'IGRT, which includes the use of implanted fiducial markers, can be adopted with IMRT, moderately hypofractionated RT or SBRT to improve treatment accuracy.'

Intra- or inter-fractional prostate movements, either rotational, translational or deformational, may potentially jeopardise the accuracy of RT for PCa [80-85]. Obtaining imaging coordinates of the target tumour and healthy tissues before and during treatment, an IGRT system helps correct the random and systematic errors due to prostate movements, resulting in a more accurate radiation delivery, and enhanced efficacy and safety of IMRT.

Despite there being no randomised dose-escalation trials on the use of IGRT systems, retrospective studies have shown that such technologies can improve biochemical and local control of PCa and reduce late GI/GU side effects. In the study conducted by the Memorial Sloan Kettering Cancer Center [86], a group of PCa patients treated with IGRT based on kilovoltage imaging of implanted

prostatic fiducial markers at a high dose of 86.4 Gy were retrospectively compared with a similar cohort of patients treated with IMRT at the same dose but without implanted fiducial markers (non-IGRT). The results revealed that IGRT was associated with significantly less grade ≥ 2 late urinary toxicity compared with non-IGRT (3-year likelihood of the toxicity: 10.4% vs 20.0%, p = 0.02). The incidence of grade ≥ 2 rectal toxicity was low in both treatment groups (IGRT: 1.0% vs non-IGRT: 1.6%, p = 0.81). In comparison with non-IGRT, IGRT was associated with significantly improved PSA relapse-free survival in high-risk patients, although no such improvement was observed in low- and intermediate-risk patients. On balance, IGRT can deliver more accurate, more effective and safer RT for PCa compared with non-IGRT.

Clinical experience in Hong Kong has shown benefits of IGRT in patients with localised PCa. A local cohort study [87] showed that IGRT was associated with significantly less frequent, shorter-lived acute grade 1/2 GI toxicity compared with non-IGRT (23.8% vs 81.0%, p = 0.001; median duration: 0.33 weeks vs 1.38 weeks, p = 0.004). The frequency of acute grade 1/2 GU toxicity was comparable between the two treatment groups (IGRT: 66.6% vs non-IGRT: 81.0%, p = 0.45). The IGRT group had a significantly shorter median PSA half-time than that of the non-IGRT group (3.36 weeks vs 5.49 weeks, p = 0.09). In short, IGRT is effective for reducing acute GI toxicity in the treatment of PCa and may have more favourable PSA kinetics compared with non-IGRT.

Commercially available IGRT systems include intra-prostatic fiducial markers, cone-beam CT, the Calypso™ 4D system, and ultrasound localisation. Of these, fiducial markers are the most widely used system in Hong Kong's institutions. Despite the disadvantages of invasive implantation procedures using TRUS and the lack of intra-fractional monitoring, fiducial markers are relatively cost-effective compared to other systems [88]. They are worthy of use for IGRT, which can improve the accuracy, efficacy and safety of treatment when combined with IMRT or other RT approaches.

Statement 6: 'Proton therapy is not recommended for routine clinical practice in the treatment of localised PCa.'

A proton beam has low incident energy and displays a spike at the tail-end of its dose distribution (i.e. the Bragg peak), with essentially no dose beyond the end range. In theory, proton therapy spares uninvolved tissues distal to a target tumour with a lower dose than photon beams [89]. Nonetheless, whether the theoretical dosimetric advantages of proton beams can translate into superior clinical efficacy compared with conventional photon RT remains uncertain. Some studies have investigated the use of proton beams in boosting conventionally fractionated EBRT for PCa [66,90-92]. However, to verify the efficacy and safety of proton therapy, randomised controlled trials are needed to directly compare its usage with photon RT. Indeed, there is an ongoing trial in the USA that investigates

proton therapy versus IMRT in men with low- or intermediate-risk PCa [93], and the results are eagerly awaited. Aside from undetermined efficacy, another concern over proton therapy is the high cost of relevant facilities. Because of the uncertainty of its superiority over conventional photon RT, proton therapy is not currently recommended as routine treatment of localised PCa.

5.5.2: Role of pelvic RT

Statement 1: 'Pelvic RT should be considered only in patients with intermediate- or high-risk PCa.'

Statement 2: 'Pelvic RT should be performed by IMRT, instead of the traditional 4-field RT technique.'

The role of pelvic RT in the treatment of PCa is unclear. In several trials that demonstrated the survival benefit of the combination of ADT and RT in men with high-risk PCa [94-96], almost all of the subjects had undergone pelvic RT, implying the importance of the procedure. In multiple surgical series [57], a significant portion of patients with high-risk PCa harboured nodal disease as confirmed

by ePLND, suggesting that it is reasonable to perform pelvic RT in men with high-risk PCa who plan to undergo RT. However, some physicians doubt the use of pelvic RT, as two randomised controlled trials demonstrated no significant benefits of the approach among patients with intermediate- or high-risk PCa [97-99]. In the randomised phase III RTOG 9413 trial, which utilised a 2×2 factorial design, although the initial result showed that, in combination with hormonal therapy, pelvic RT improved progression-free survival (PFS) compared with prostate-only RT [97], an updated analysis of the trial found no significant difference in PFS or OS between the two RT approaches among the patients alive after a median follow-up of 7 years [98]. Another trial, GETUG-01, found no significant difference in PSA-PFS between pelvic and prostate-only RT [99], but a main limitation of that study was that the upper border of the pelvic RT used was at the S1/S2 level, which is lower than the L5/S1 or L4/L5 in pelvic RT that is typically used for capturing at-risk pelvic nodes. To further investigate the role of pelvic RT, RTOG 0924, a phase III randomised trial [100], will recruit 2,500 men with unfavourable intermediate- or high-risk PCa to receive ADT plus either prostate-alone or pelvic RT, with OS as the primary endpoint.

Because of this mixed evidence, most cancer centres in Hong Kong have not performed pelvic RT routinely in the treatment of PCa. At those centres that have experience in pelvic RT, the approach has been reserved only for patients with intermediate- or high-risk PCa, not low-risk disease. Meanwhile, pelvic RT should be performed with IMRT because of its dosimetric advantage over the traditional

four-field RT technique. A Hong Kong study showed that, when used in pelvic RT, RapidArc™ IMRT had superior dosimetric outcomes and treatment delivery efficiency compared with conventional IMRT [101].

5.5.3: Brachytherapy

Although the panel reviewed a number of articles on the efficacy and tolerability of brachytherapy [102-107], no consensus statements on this treatment option were reached. Indeed, the experience using brachytherapy in Hong Kong is limited, possibly because of the lack of expertise, high treatment and capital costs, and the wide acceptance of RP and EBRT among physicians and patients.

5.5.4: Post-RP RT

Statement 1: 'Post-RP patients with the following adverse pathological features could have a higher recurrence risk: (a) positive surgical margins; (b) seminal vesicle invasion; (c) extraprostatic spread; and (d) Gleason score ≥ 8.'

Of patients with localised PCa who have undergone RP, up to one-third may experience a PSA

biochemical recurrence within 10 years [108]. If left untreated, a significant proportion of patients

with recurrent disease may develop distant metastasis at 8 years after an increase in their PSA levels,

followed by death from PCa at 5 years after the onset of metastatic disease [109]. In post-RP patients,

positive surgical margins, seminal vesicle invasion, extraprostatic spread, and a Gleason score of ≥ 8

are considered to be factors that could increase the risk of developing recurrent disease [109-113].

Statement 2: 'A biochemical recurrence after RP is defined as the detection of a PSA level at $\geq$

0.2 ng/mL, with a second confirmatory level detected at $\geq$ 0.2 ng/mL, or the detection of one

PSA reading of > 0.4 ng/mL after RP.'

Statement 3: 'Adjuvant RT is the administration of RT to post-RP patients with adverse

pathological features prior to evidence of disease recurrence (especially with an undetectable

PSA level).'

Statement 4: 'Salvage RT is the administration of RT to the prostatic bed and possibly to the

surrounding tissues, including lymph nodes, in post-RP patients with a detectable PSA

recurrence but no evidence of distant metastatic disease.'

After discussion, the panel decided to adopt the definitions of post-RP biochemical recurrence, adjuvant and salvage RT from a guideline established jointly by the American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) [114], which has been widely endorsed by local PCa experts. These definitions are expected to facilitate decision-making in the management of men with localised PCa who have undergone RP.

Statement 5: 'Adjuvant RT is an option for patients with adverse pathological features, with consideration of the patient's history, functional status, values and preferences, and his tolerance for the potential toxicities and impact on quality of life due to RT.'

In three randomised controlled trials and their follow-up analyses [115-120], adjuvant RT has been proven to improve biochemical control among patients with adverse pathological features following RP. One of the three trials, SWOG 8794, also showed that adjuvant RT was associated with significantly increased OS [116]. A retrospective cohort study demonstrated that adjuvant RT, compared with salvage RT, was associated with reduced biochemical recurrence, distant metastasis, and mortality for patients with adverse pathology [121]. Similar findings were presented in a Spanish

nationwide cohort study, in which adjuvant RT yielded better 2- and 5-year biochemical relapse-free survival outcomes but equivalent OS rates compared with salvage RT [122].

However, one of the problems with adjuvant RT is the possibility of over-treatment. Local clinical experience has shown that about half of post-RP patients with adverse pathology do not develop recurrent disease in their lifetime. Given the possibility of over-treatment, adjuvant RT is not necessarily preferable to salvage RT. Another concern over adjuvant RT is that it should be done within 3–4 months after surgery, during which patients may not have fully recovered and may be RT-intolerant. Moreover, from a patient's perspective, if the post-RP PSA level remains low, the benefit of adjuvant RT may appear insignificant.

Although the evidence supports the use of adjuvant RT in post-RP patients with adverse pathology, a variety of considerations should be discussed thoroughly with the patient and his family before the treatment option is planned.

Statement 6: 'Salvage RT should be considered in patients with a persistently detectable post-RP PSA level.'

In the two randomised controlled trials, SWOG 8794 [115] and EORTC 22911 [117], some of the enrolled patients had a detectable PSA level at baseline (> 0.2 ng/mL vs ≤ 0.2 ng/mL as undetectable) in the early post-RP period (< 18 weeks). The subgroup analyses in the two respective trials showed that RT improved metastasis-free survival [116] and biochemical recurrence-free survival [118], with no significant difference attributable to the baseline post-RP PSA level (detectable vs undetectable). These results imply that, apart from adjuvant RT (initiated at an undetectable PSA level), salvage RT (at a detectable PSA level) can be considered as an alternative to treat post-RP patients with adverse pathology.

Statement 7: 'It is recommended to regularly monitor PSA levels in post-RP patients, in order to enable early administration of salvage RT whenever applicable.'

Statement 8: 'Early salvage RT should be considered when there is a detectable PSA level, i.e. $\geq$ 0.2 ng/mL.'

Salvage RT leads to better biochemical control when initiated at a lower PSA level, as shown in a systematic review [123]. Hence, physicians should regularly monitor the PSA levels in patients after RP, in order to initiate salvage RT as early as the PSA level becomes detectable, i.e. ≥ 0.2 ng/mL.

Statement 9: 'The minimum dose for salvage RT is recommended to be 64 Gy.'

To carry out salvage RT, IMRT, instead of 3D-CRT, should be considered, because it is associated with a lower risk of late GI toxicity [124,125]. In a retrospective analysis [126], there was a dose-response relationship between salvage RT (60–70 Gy) and relapse-free survival. According to an ASTRO/AUA guideline [114], 64 Gy is recommended as the minimum dose for salvage RT, ensuring effective disease control.

Statement 10: 'Regarding the clinical target volume for post-RP RT, the RTOG consensus guidelines should be followed.'

In the RTOG consensus [127], the prostate fossa clinical target volume for post-RP RT for PCa was defined and presented as a CT image atlas for physician reference. The definition is relevant and applicable to the local clinical setting.

Statement 11: 'The combination of salvage RT and hormone therapy in the treatment of localised PCa remains investigational.'

Data from randomised controlled trials investigating the use of salvage RT plus hormonal therapy in the treatment of localised PCa are few. In the RTOG 9601 randomised trial [128], the combination of 2-year bicalutamide, an antiandrogen, and salvage RT improved overall, disease-specific and metastasis-free survival compared with salvage RT alone in patients with recurrent disease after RP and a detectable PSA level of 0.2–4 ng/mL. From this, we may postulate that, for patients with a higher PSA level or pN1 disease at the time of salvage RT, the addition of hormonal therapy, including ADT, may be considered. RADICALS, an ongoing randomised trial in the UK [129], will investigate the outcomes of the combination of luteinising-hormone releasing hormone (LHRH) and salvage RT versus the combination of bicalutamide and salvage RT. At the time of this, the combination of salvage RT and hormonal therapy in the treatment of localised PCa remains investigational.

5.5.5: Management of post-RT side effects

Statement 1: 'Treatment approaches to RT-induced proctitis include topical agents (e.g. steroid suppositories, formalin), oral medications, hyperbaric oxygenation (HBO), and endoscopic interventions (e.g. argon plasma coagulation [APC]).'

Proctitis is a common adverse event observed in patients treated with RT. Although the optimal management of RT-induced proctitis is ill-defined, there are a variety of possible treatment approaches, including topical agents, oral medications, HBO, and endoscopic interventions, such as APC. To treat newly developed proctitis, steroid suppositories can be initiated. If necessary, topical formalin can be applied with a cotton swab only to the area involved. HBO can be considered in patients with persistent severe proctitis. APC is reserved for patients with severe bleeding refractory to other measures, but its risk for further rectal injuries and clinical deterioration should be noted.

Statement 2: 'RT-induced proctitis is diagnosed endoscopically, without the need for histological confirmation, as biopsies may exacerbate the disease and are unlikely to provide useful information.'

In local clinical experience, proctitis in patients treated with RT can be diagnosed endoscopically, without the need for biopsies, which may only exacerbate the disease and are unlikely to offer useful information on diagnosis or treatment.

Statement 3: 'Before the treatment of cystitis, causes of haematuria other than RT, e.g. urinary calculi, tumours, infections, bleeding anomalies (medications and coagulopathies) and other non-bladder sources of bleeding (renal, ureter and prostate urethra), need to be ruled out by urine and serum tests, cystoscopy, and imaging.'

Apart from proctitis, haemorrhagic cystitis is another frequent problem experienced by patients following RT. To assess whether cystitis is induced by RT, urine and serum studies, cystoscopy and imaging should be performed to rule out other causes of haematuria, such as urinary calculi, tumours, infections, bleeding anomalies (due to medications or coagulopathies), and other non-bladder sources of bleeding (e.g. the kidneys, ureter or prostatic urethra).

Statement 4: 'Treatment modalities for haemorrhagic cystitis include continuous bladder irrigation, instillation of alum or formalin, fulguration with electro-cautery, HBO, internal iliac embolisation, intra-vesical hydrostatic pressure therapy, and cystectomy with urinary diversion (for extreme cases).'

While RT-induced cystitis is mostly self-limiting, a range of treatment modalities can be considered when necessary. These include continuous bladder irrigation by three-way catheter with evacuation of clots, instillation of alum or formalin, fulguration with electro-cautery, HBO therapy, internal iliac embolisation, intra-vesical hydrostatic pressure therapy and in extreme cases, cystectomy with urinary diversion.

5.6: Androgen deprivation therapy (ADT)

Statement 1: 'ADT monotherapy should not be used in patients with localised PCa, regardless of the risk category.'

As a non-radical treatment approach, ADT monotherapy is not a standard of care for localised PCa. A large, population-based study suggested that ADT monotherapy worsened OS of men with localised PCa compared with observation [130]. Randomised controlled trials [131,132] showed that ADT alone had significantly less OS benefits compared with the combination of RT and ADT among men with locally advanced PCa. Unless contraindications to radical treatment are present, ADT alone should not be considered in men with localised PCa.

Statement 2: 'ADT, with or without definitive local treatment, is not recommended in patients with low-risk PCa.'

As per the post hoc risk analysis of the RTOG 9408 trial [133], among patients with low-risk PCa, the addition of short-term ADT to RT did not significantly improve OS or disease-specific survival compared with RT alone. In view of this outcome, along with the evidence against the use of ADT monotherapy for localised PCa [130-132], ADT should not be used in men with low-risk PCa under any circumstances.

Statement 3: 'Neoadjuvant ADT for RP is not recommended.'

Although it can help to achieve pathological down-staging and improve positive surgical margin rates [134], neoadjuvant ADT before RP does not improve OS or disease-free survival among patients with localised PCa [135,136]. A Japanese study suggested that neoadjuvant ADT for low-risk PCa may increase the risk of biochemical recurrence after RP, because of up-regulation of lymphangiogenesis-related parameters [137]. In addition, there is a concern that pre-RP neoadjuvant ADT may complicate the procedure of surgery, especially nerve-sparing surgery, because of induced fibrosis. Consistent with international guidelines [17,58], the panel's consensus was that neoadjuvant ADT for RP is not recommended in patients with localised PCa.

Statement 4: 'Adjuvant ADT after RP is not recommended in patients with pN0 disease.'

Adjuvant ADT following RP is not recommended in patients with localised (pN0) PCa, because despite the potential to improve PFS, it is unable to significantly increase OS in men with localised PCa [138]. Regarding adjuvant antiandrogen, a randomised trial found that its use improved neither PFS nor OS in men with localised PCa after RP [139].

Statement 5: 'When RT is planned for patients with intermediate-risk PCa, neoadjuvant ADT (for 4–6 months) can be considered.'

The combination of neoadjuvant ADT and RT can lead to significant survival benefits in men with intermediate-risk PCa compared with RT alone [133,140-143]. However, the optimal timing and duration of neoadjuvant ADT remain ill-defined. In the RTOG 9408 trial [133], the use of ADT for 4 months (starting 2 months before RT) was effective to improve disease-specific survival and OS among patients with intermediate-risk PCa. The 4-month ADT schedule was further supported by the RTOG 9910 trial [141], which found that extending the ADT duration to 7 months before RT did not improve survival outcomes. Yet, a retrospective study conducted in Japan showed that neoadjuvant ADT lasting for ≥ 6 months improved biochemical recurrence-free survival in patients with intermediate-risk PCa [143]. Therefore, neoadjuvant ADT for 4–6 months can be given before the initiation of RT for intermediate-risk PCa.

Statement 6: 'When RT is planned for patients with high-risk PCa, neoadjuvant (for 4–6 months) and adjuvant ADT (for 2–3 years) are recommended.'

Similar to the efficacy in intermediate-risk PCa, ADT in combination with RT is able to significantly improve survival outcomes in men with high-risk PCa compared with RT alone [144]. Regarding the duration of ADT, the DART01/05 GICOR randomised controlled trial showed that, compared with only 4 months of neoadjuvant and concomitant ADT, additional adjuvant ADT continuing for 2 years after RT was associated with better biochemical control and OS among patients with high-risk PCa [96]. Based on a review [144], in addition to RT, ADT for ≥ 2 years can improve survival outcomes for locally advanced PCa. Based on the evidence, neoadjuvant (for 4–6 months) and adjuvant ADT (for 2–3 years) should be considered in patients with high-risk PCa who are expected to receive RT.

Statement 7: 'To reduce the risk of ADT-related bone fracture, supplemental calcium and vitamin D should be considered in patients receiving ADT.'

Although short-term ADT added to RT causes no significant impact on health-related quality of life [145], long-term ADT may increase the risk of osteoporotic fracture in patients with PCa [146-148]. In these cases, calcium and vitamin D supplements should be considered as prophylaxis to prevent osteoporosis in patients treated with ADT.

Bone protective agents, including bisphosphonates and denosumab, were also discussed by the panel members; however, it was stressed that patients should be alerted to the risk of osteonecrosis of the jaw associated with these medications [149]. Considering the benefit-risk balance, physicians seldom prescribe these agents for patients with localised PCa.

Statement 8: 'The fasting lipid profile and cardiovascular risk of patients receiving ADT should be assessed regularly.'

Aside from bone fractures, cardiovascular side effects are another concern about the use of ADT in patients with PCa. Although the analyses of the RTOG 9408 and 9202 trials found that ADT, irrespective of the duration, did not increase the risk of cardiovascular mortality in men with localised PCa [150,151], other studies have revealed that ADT could increase weight gain and interfere with lipid profiles, potentially resulting in an elevated risk of cardiovascular events [152,153]. Some research suggested that the cardiovascular risk may depend on the modalities of ADT, but more detailed prospective evidence is required to verify the hypothesis [154]. In view of the clinical data, regular assessments of lipid profiles and cardiovascular risk should be considered as precautionary measures in patients treated with ADT.

5.7: Other therapies

Statement 1: 'Novel therapy and chemotherapy for localised PCa remain investigational and are not recommended for routine clinical practice.'

Researchers have started to study the use of novel agents, such as androgen receptor (AR) pathway inhibitors, in the treatment of localised PCa. Phase II studies have shown that the addition of neoadjuvant abiraterone to ADT prior to RT or RP can be effective for achieving prostatic androgen suppression, possibly reducing tumour burden in men with intermediate- or high-risk PCa [155,156]. Enzalutamide also may facilitate the treatment of PCa via the inhibition of the AR pathway. In a study done in patients with intermediate- and high-risk PCa [157], neoadjuvant enzalutamide in combination with dutasteride and leuprolide before RP was effective for lowering concentrations of intraprostatic testosterone and PSA, suggesting a potential reduction in cancer burden.

Chemotherapy for the treatment of localised PCa is another emerging research topic. In a phase II trial of men with high-risk PCa [158], neoadjuvant paclitaxel, carboplatin and estramustine plus ADT before RP appeared to reduce the rates of biochemical recurrence and metastasis compared to RP alone, but the results were not statistically significant. Another phase II trial showed that, among men

with locally advanced and high-risk PCa, neoadjuvant docetaxel plus complete androgen blockade prior to RP resulted in significant downstaging without pathological complete response and possibly improved the 5-year biochemical recurrence-free survival, but severe haematologic toxicities were frequently observed [159]. Before more robust evidence is established, neoadjuvant chemo-hormonal therapy before RP should not be adopted in routine clinical practice, because of its high toxicity and unproven benefit.

Chemotherapy in addition to RT for the treatment of localised PCa has been attempted in some clinical trials. In the GETUG 12 randomised trial conducted in men with high-risk PCa [160], neoadjuvant docetaxel/estramustine plus ADT before local treatment (primarily RT) was associated with a higher PSA response rate and had a favourable safety profile compared to ADT alone, but the impacts on relapse and survival need to be further assessed. Adjuvant chemotherapy after RT has also been studied. The RTOG 0521 phase III trial showed that, for high-risk localised PCa, adjuvant docetaxel and prednisone plus ADT after RT was associated with a higher 4-year OS rate (93% vs 89%; one-sided p = 0.03, HR 0.68, 95% CI 0.44–1.03) compared with ADT alone after RT, with an acceptable toxicity profile; however, the one-sided p value used in the statistical analysis is viewed as a limitation of the result, and additional research is warranted to investigate the long-term impact of adjuvant chemotherapy following RT [161]. With that benefit still under verification, the NCCN has recently suggested that docetaxel (without prednisone) may be administered after RT in selected

patients with high-risk localised PCa who are fit for chemotherapy [41]. Nevertheless, in view of limited evidence, especially in the Chinese population, our panel have chosen to adopt a conservative stance and do not recommend the combination of chemotherapy and local treatment (RT or RP) for localised PCa.

Aside from AR pathway inhibitors and chemotherapy, other novel agents, such as those targeting different growth factor receptors and immunotherapies, are under investigation for the treatment of localised PCa [162]. To date, novel therapies and chemotherapy for localised PCa remain investigational and should not be used in routine clinical practice.

Part 6: Follow-up and monitoring after definitive local treatment

6.1: Recurrence after surgery

Statement 1: 'A reasonable schedule for PSA monitoring after RP is to test the PSA level: (1) every 3 months in year 1; (2) every 6 months in year 2; and (3) annually thereafter.'

After reviewing several international guidelines [41,58,163] and considering their practicability and suitability in the locality, the panel decided to adopt the PSA testing schedule proposed by a group of PCa experts in Canada for men who have undergone RP for localised PCa [163].

Statement 2: 'It is recommended to check the PSA level of post-RP patients annually until the end of their life, but physicians should determine at their discretion whether to stop testing in patients who are unlikely to benefit from salvage therapy, e.g. those with a life expectancy of < 5 years.'

Although an annual PSA check is recommended in post-RP patients, some circumstances may allow for the termination of follow-ups. According to a long-term review done in Japan [164], if a patient's PSA level is undetectable by ultrasensitive assay for 5 consecutive years, the PSA monitoring may be halted because the risk of subsequent biochemical recurrence will be extremely low. Another situation in which PSA testing may be stopped is when the patient may no longer benefit from salvage therapy in view of life expectancy [163].

6.2: Recurrence after RT

Statement 1: 'A biochemical failure after RT, with or without hormone therapy, is defined as a rise in the PSA level by ≥ 2 ng/mL above the PSA nadir.'

Based on clinical experience, men who have received RT for localised PCa often take 6–18 months to reach a PSA nadir compared with 6 weeks to 2 months for patients who have undergone RP. To define a biochemical failure after RT, the Phoenix definition has been the international standard for the past decade [165].

Statement 2: 'The definition of secondary biochemical progression after post-op salvage RT remains undetermined but is usually considered as a rise in the PSA level by ≥ 0.2 ng/mL above the post-RT nadir.'

Despite a lack of high-level agreement in the literature, the definition of secondary biochemical progression after post-op salvage RT can be considered as a rise in the PSA level by ≥ 0.2 ng/mL above the post-RT nadir, as per a large retrospective analysis series conducted in the USA [166].

Statement 3: 'A reasonable schedule for PSA monitoring after RT is to test the PSA level: (1) 6 months after treatment completion; (2) every 6 months until the end of year 5; and (3) annually thereafter.'

Similar to that for men who have undergone RP (Section 6.1, Statement 1), the schedule for PSA testing in patients who have received RT was adopted from the Canadian expert group [163].

6.3: Diagnostic imaging after biochemical relapse

Statement 1: 'When salvage RT is planned after RP in patients with a PSA level < 1 ng/mL or a PSA doubling time (PSADT) $\geq$ 6 months, no diagnostic imaging is recommended.'

Referring to Section 5.5.4, Statement 8, when there is a detectable post-RP PSA level, i.e. $\geq$ 0.2 ng/mL, early salvage RT should be considered. To treat biochemical recurrence after RP in patients with a PSA level < 1 ng/mL or a PSADT $\geq$ 6 months, salvage RT is often planned; however, no diagnostic imaging is recommended because the possibility of detecting lymph node or distant

metastases is low, either by a bone scan, CT scan or PSMA PET [24,167,168]. Consequently, the imaging results are unlikely to affect the treatment decision.

Statement 2: 'In the setting of post-RP biochemical recurrence, in cases of a PSA level ≥ 1 ng/mL or a PSADT < 6 months, whole-body PSMA PET-CT can be considered to detect the presence of pelvic lymph node or distant metastases, in order to guide the treatment decision.'

According to a systematic review and meta-analysis of 16 articles involving 1,309 patients [24], positive rates of biochemical recurrence on ^{68}Ga-PSMA PET after RP increased with pre-PET PSA levels. For the PSA ranges 0–0.2, 0.2–1, 1–2 and > 2 ng/mL, 42%, 58%, 76% and 95% of the scans, respectively, were positive on metastases. In addition, the review found that a shorter PSADT was associated with increased ^{68}Ga-PSMA PET positivity (PSADT ≥ 6 vs < 6 months, positivity = 64% vs 92%) [24]. Based on these results, for post-RP biochemical recurrence, if a PSA level is ≥ 1 ng/mL or PSADT is < 6 months, whole-body PSMA PET-CT can be considered to detect the presence of pelvic lymph node or distant metastases, in order to assess whether to use salvage RT or other treatment measures. However, it was noted that further prospective trials are eagerly awaited to confirm the clinical benefits of this imaging modality.

Statement 3: 'In the setting of post-RP biochemical recurrence, in cases of a PSA level ≤ 10 ng/mL, whole-body PSMA PET-CT may be more sensitive than a bone scan or CT scan in the detection of pelvic lymph node or distant metastases.'

Based on retrospective analyses [167,168], patients with biochemical recurrence after RP have a low probability of positive bone scan or positive CT scan, unless they have a high PSA level (> 10 ng/mL). As discussed in Statement 2, ^{68}Ga-PSMA PET is worth considering in patients with post-RP biochemical recurrence who have a PSA level ≥ 1 ng/mL. Therefore, in the setting of biochemical recurrence after RP, in cases of a PSA level ≤ 10 ng/mL, whole-body PSMA PET-CT may be more sensitive than a bone scan or CT scan in the detection of pelvic lymph node or distant metastases.

Statement 4: 'In the setting of post-RT biochemical recurrence, in cases of a PSA level > 10 ng/mL, further imaging using bone scan, CT scan or whole-body PSMA PET-CT scan can be considered to guide the treatment decision.'

Based on the evidence discussed for Statements 2 and 3 [24,167,168], regarding biochemical recurrence after RT or RP, in cases of a PSA level > 10 ng/mL, either a bone scan, CT scan or whole-body PSMA PET-CT is sensitive enough for the detection of lymph node or distant metastases, and will help to guide the treatment decision.

Part 7: Management of *de novo* pelvic nodal disease (with evidence of pelvic lymph node metastasis on presentation, but M0)

Statement 1: 'In patients diagnosed with N1M0 disease on presentation, ADT alone +/- EBRT to the primary tumour can be considered.'

In a post hoc analysis of the STAMPEDE trial [169], among patients with N+M0 disease, RT (prostate +/- whole pelvis) plus ADT was associated with better failure-free survival (FFS) compared with ADT alone (HR 0.48, 95% CI 0.29–0.79; 2-year FFS: 81% vs 53%). Similarly, a large retrospective study done in the USA [170] showed that, compared with ADT alone, ADT plus RT was associated with a lower risk of 5-year all-cause mortality (HR 0.50, 95% CI 0.37–0.67, two-sided P < 0.001; crude OS rate: 71.5% vs 53.2%) in men with cN+M0 PCa. These results suggest that long-term

ADT +/- RT can be considered in patients with N+M0 disease. In the panel's experience, surgery is

seldom performed for N+M0 disease.

Statement 2: 'Survival benefits of immediate ADT after RP in patients with pathological pelvic

lymph node metastasis remain uncertain.'

Although one study, conducted in an era when serum PSA testing was not widely used for the

diagnosis of PCa, showed that immediate antiandrogen therapy after surgery improved survival and

reduced the risk of recurrence in patients with N+ PCa [171], the more recent SEER-Medicare cohort

study [172] revealed that deferring immediate ADT in men with N+ PCa after RP did not significantly

compromise survival. In the EORTC 30846 randomised trial [173], among patients with pN1–3 M0

PCa without local treatment of the primary tumour, no significant difference in OS or PCa-specific

survival was observed between immediate and delayed ADT, although the trial was underpowered to

confirm non-inferiority. In view of the evidence, survival benefits of immediate ADT after RP in men

with pN+ PCa remain uncertain.

Statement 3: 'Men with low-volume nodal disease (two pelvic lymph nodes) in the presence of intermediate- or high-grade, non-specimen-confined disease, and those with intermediate-volume nodal disease (three or four pelvic lymph nodes) represent the ideal candidates for adjuvant RT after surgery.'

In a retrospective cohort study of men with pN1 PCa treated with RP and ePLND [174], the multivariable analysis showed that adjuvant RT plus ADT was associated with reduced cancer-specific mortality compared with adjuvant ADT alone (HR 0.37; P < 0.001). However, the sub-group analysis found that only two risk groups of men benefited from adjuvant RT plus ADT: (1) patients with a positive lymph node (PLN) count of 2, Gleason score 7–10, pT3b/pT4 stage, or positive surgical margins (HR 0.30; P < 0.002); and (2) patients with a PLN count of 3–4 (HR 0.21; P < 0.02), irrespective of other tumour characteristics. These results imply that men with low-volume nodal disease (two PLNs) in the presence of intermediate- to high-grade, non-specimen-confined disease and those with intermediate-volume nodal disease (three to four PLNs) represent the ideal candidates for adjuvant RT after surgery.

Statement 4: 'In patients with pelvic lymph node recurrence after surgery, the combination of ADT and salvage pelvic RT can be considered.'

Based on the above evidence regarding the treatment of N+M0 disease, the combination of ADT and salvage pelvic RT can be considered for the treatment of pelvic lymph node recurrence after surgery, although more research should be done. In the panellists' experience, surgery is seldom performed for post-RP pelvic lymph node recurrence.

Discussion

Based on current published evidence and the panellists' clinical experience, consensus statements on the management of clinically localised PCa for Hong Kong have been established for dissemination. Adapted from the consensus statements, two figures demonstrate the key processes of the diagnostic work-up for suspicious PCa (Figure 1) and the treatment algorithm (Figure 2). Of note, there are still some questions remaining in the management of localised PCa, in particular those related to the clinical benefits of new-generation imaging tools, the survival benefits of salvage RT plus ADT, the use of novel therapy, and the benefits of immediate ADT after RP in men with pN+ PCa. Prospective trials, especially conducted in Chinese or Asian patients, are eagerly awaited to address these queries. In the face of emerging data from ongoing clinical research, consensus statements are subject to regular review and necessary updating. In conclusion, these statements are aimed to serve as recommendations for physicians in Hong Kong for the management of localised PCa.

Acknowledgements

Conflict of Interest

Conflict of interest statements from all panellists are listed in Appendix S3.

References

1.   Hospital Authority. Hong Kong Cancer Registry [Internet]. Hospital Authority; 2018. Available at: http://www3.ha.org.hk/cancereg/. Accessed 25 January 2018.

2.   Yee CH, Ng CF. Urological malignancy in Hong Kong: the trend and the practice. *Jpn J Clin Oncol* 2015; 45: 1103–6.

3.   Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. *JAMA* 2009; 302: 1685–92.

4.   Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009; 360: 1320–8.

5.   Poon DM, Chan CK, Chan TW et al. Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. *BJU Int* 2018; 121: 703–15.

6.   Linstone HA, Turoff M. The Delphi Method: Techniques and Applications. Boston, MA: Addison-Wesley Publishing Co., Inc; 2002.

7.   Gretzer MB, Partin AW. PSA levels and the probability of prostate cancer on biopsy. *European Urology Supplements* 2002; 1: 21–7.

8.   Gosselaar C, Roobol MJ, Roemeling S, Schroder FH. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. *Eur Urol* 2008; 54: 581–8.

9.   Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. *JAMA* 1998; 279: 1542–7.

10.   Ng CF, Chiu PK, Lam NY, Lam HC, Lee KW, Hou SS. The prostate health index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. *Int Urol Nephrol* 2014; 46: 711–7.

11.   Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer

detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. *Eur Urol* 2015; 68: 438–50.

12.   Wegelin O, van Melick HHE, Hooft L et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? *Eur Urol* 2017; 71: 517–31.

13.   van Hove A, Savoie PH, Maurin C et al. Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. *World J Urol* 2014; 32: 847–58.

14.   Ma WK, Ho BS, Lai AS et al. Multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy with semi-robotic navigation in the Chinese population: initial results. *Asian J Androl* 2018; 20: 93–4.

15.   Ahmed HU, El-Shater Bosaily A, Brown LC et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet* 2017; 389: 815–22.

16.   NICE. Prostate cancer: diagnosis and management (update) – Draft for consultation, December 2018 [Internet]. NICE; 2018. Available at:

https://www.nice.org.uk/guidance/GID-NG10057/documents/draft-guideline. Acessed 20 December 2018.

17. Mottet N, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. *Eur Urol* 2017; 71: 618–29.

18. de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. *Eur Urol* 2016; 70: 233–45.

19. Somford DM, Hamoen EH, Futterer JJ et al. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. *J Urol* 2013; 190: 1728–34.

20. Tollefson MK, Karnes RJ, Rangel LJ, Bergstralh EJ, Boorjian SA. The impact of clinical stage on prostate cancer survival following radical prostatectomy. *J Urol* 2013; 189: 1707–12.

21. Mikel Hubanks J, Boorjian SA, Frank I et al. The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes. *Urol Oncol* 2014; 32: 26.e1–7.

22. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. *Nat Rev Urol* 2016; 13: 226–35.

23.   Pyka T, Okamoto S, Dahlbender M et al. Comparison of bone scintigraphy and (68)Ga-PSMA

PET for skeletal staging in prostate cancer. *Eur J Nucl Med Mol Imaging* 2016; 43: 2114-21.

24.   Perera M, Papa N, Christidis D et al. Sensitivity, specificity, and predictors of positive

(68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate

cancer: a systematic review and meta-analysis. *Eur Urol* 2016; 70: 926–37.

25.   Merdan S, Womble PR, Miller DC et al. Toward better use of bone scans among men with

early-stage prostate cancer. *Urology* 2014; 84: 793–8.

26.   Sartor O, Eisenberger M, Kattan MW, Tombal B, Lecouvet F. Unmet needs in the prediction

and detection of metastases in prostate cancer. *Oncologist* 2013; 18: 549–57.

27.   Sammon JD, Abdollah F, D'Amico A et al. Predicting life expectancy in men diagnosed with

prostate cancer. *Eur Urol* 2015; 68: 756–65.

28.   Cho H, Mariotto AB, Mann BS, Klabunde CN, Feuer EJ. Assessing non-cancer-related health

status of US cancer patients: other-cause survival and comorbidity prevalence. *Am J Epidemiol* 2013;

178: 339–49.

29.   Van Hemelrijck M, Folkvaljon Y, Adolfsson J et al. Causes of death in men with localized

prostate cancer: a nationwide, population-based study. *BJU Int* 2016; 117: 507–14.

30.	Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. *J Clin Oncol* 2011; 29: 1335–41.

31.	Nieder C, Dalhaug A, Pawinski A, Aandahl G, Norum J. Comorbidity, use of common medications, and risk of early death in patients with localized or locally advanced prostate cancer. *ScientificWorldJournal* 2011; 11: 1178–86.

32.	Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. *Am J Surg Pathol* 2016; 40: 244–52.

33.	Epstein JI, Zelefsky MJ, Sjoberg DD et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. *Eur Urol* 2016; 69: 428–35.

34.	Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part B: prostate and bladder tumours. *Eur Urol* 2016; 70: 106–19.

35.	Nelson BA, Shappell SB, Chang SS et al. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. *BJU Int* 2006; 97: 1169–72.

36.   Tsao CK, Gray KP, Nakabayashi M et al. Patients with biopsy Gleason 9 and 10 prostate cancer have significantly worse outcomes compared to patients with Gleason 8 disease. *J Urol* 2015; 194: 91–7.

37.   Rusthoven CG, Waxweiler TV, DeWitt PE, Flaig TW, Raben D, Kavanagh BD. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. *Urol Oncol* 2015; 33: 71.e11–9.

38.   D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. *JAMA* 2005; 294: 440–7.

39.   Venkitaraman R, Norman A, Woode-Amissah R et al. Prostate-specific antigen velocity in untreated, localized prostate cancer. *BJU Int* 2008; 101: 161–4.

40.   D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA* 1998; 280: 969–74.

41.   NCCN Guidelines®. Prostate Cancer Version 2.2017 – February 21, 2017.

42.   Bill-Axelson A, Holmberg L, Garmo H et al. Radical prostatectomy or watchful waiting in early prostate cancer. *N Engl J Med* 2014; 370: 932–42.

43.   Wilt TJ, Jones KM, Barry MJ et al. Follow-up of prostatectomy versus observation for early prostate cancer. *N Engl J Med* 2017; 377: 132–42.

44.   Klotz L. Active surveillance for low-risk prostate cancer. *Curr Urol Rep* 2015; 16: 24.

45.   Klotz L, Vesprini D, Sethukavalan P et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. *J Clin Oncol* 2015; 33: 272–7.

46.   Tosoian JJ, Mamawala M, Epstein JI et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. *J Clin Oncol* 2015; 33: 3379–85.

47.   Hamdy FC, Donovan JL, Lane JA et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. *N Engl J Med* 2016; 375: 1415–24.

48.   Garisto JD, Klotz L. Active surveillance for prostate cancer: how to do it right. *Oncology (Williston Park)* 2017; 31: 333–40, 45.

49.   Donis Canet F, Sanchez Gallego MD, Arias Funez F et al. Cryotherapy versus high-intensity focused ultrasound for treating prostate cancer: oncological and functional results. *Actas Urol Esp* 2017.

50.   Bass EJ, Ahmed HU. Focal therapy in prostate cancer: A review of seven common controversies. *Cancer Treat Rev* 2016; 51: 27–34.

51.   Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med* 2005; 352: 1977–84.

52.   Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med* 2011; 364: 1708–17.

53.   Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. *Cochrane Database Syst Rev* 2017; 9: Cd009625.

54.   Lo KL, Ng CF, Lam CN, Hou SS, To KF, Yip SK. Short-term outcome of patients with robot-assisted versus open radical prostatectomy: for localised carcinoma of prostate. *Hong Kong Med J* 2010; 16: 31–5.

55.   Chang Y, Qu M, Wang L et al. Robotic-assisted laparoscopic radical prostatectomy from a single Chinese center: a learning curve analysis. *Urology* 2016; 93: 104–11.

56.   Briganti A, Blute ML, Eastham JH et al. Pelvic lymph node dissection in prostate cancer. *Eur Urol* 2009; 55: 1251–65.

57.   Bianchi L, Gandaglia G, Fossati N et al. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia* 2017; 84: 9–19.

58. Sanda MG, Cadeddu JA, Kirkby E et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. *J Urol* 2018; 199: 990–7.

59. Yaxley JW, Dagher J, Delahunt B, Egevad L, Srigley J, Samaratunga H. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. *World J Urol* 2018; 36: 15–20.

60. Wang W, Huang QM, Liu FP, Mao QQ. Effectiveness of preoperative pelvic floor muscle training for urinary incontinence after radical prostatectomy: a meta-analysis. *BMC Urol* 2014; 14: 99.

61. Anderson CA, Omar MI, Campbell SE, Hunter KF, Cody JD, Glazener CM. Conservative management for postprostatectomy urinary incontinence. *Cochrane Database Syst Rev* 2015; 1: Cd001843.

62. Montorsi F, Brock G, Stolzenburg JU et al. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). *Eur Urol* 2014; 65: 587–96.

63. Gandaglia G, Suardi N, Cucchiara V et al. Penile rehabilitation after radical prostatectomy: does it work? *Transl Androl Urol* 2015; 4: 110–23.

64. Kuban DA, Tucker SL, Dong L et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. *Int J Radiat Oncol Biol Phys* 2008; 70: 67–74.

65. Al-Mamgani A, van Putten WL, Heemsbergen WD et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2008; 72: 980–8.

66. Zietman AL, Bae K, Slater JD et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95–09. *J Clin Oncol* 2010; 28: 1106–11.

67. Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. *JAMA* 2005; 294: 1233–9.

68. Bauman G, Rumble RB, Chen J, Loblaw A, Warde P. Intensity-modulated radiotherapy in the treatment of prostate cancer. *Clin Oncol (R Coll Radiol)* 2012; 24: 461–73.

69. Hartford AC, Palisca MG, Eichler TJ et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for intensity-modulated radiation therapy (IMRT). *Int J Radiat Oncol Biol Phys* 2009; 73: 9–14.

70. Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. *Health Technol Assess* 2010; 14: 1–108, iii–iv.

71. Poon DM, Chan SL, Leung CM et al. Efficacy and toxicity of intensity-modulated radiation therapy for prostate cancer in Chinese patients. *Hong Kong Med J* 2013; 19: 407–15.

72. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? *Int J Radiat Oncol Biol Phys* 2001; 50: 1021–31.

73. Incrocci L, Wortel RC, Alemayehu WG et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol* 2016; 17: 1061–9.

74. Dearnaley D, Syndikus I, Mossop H et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. *Lancet Oncol* 2016; 17: 1047–60.

75. Catton CN, Lukka H, Gu CS et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. *J Clin Oncol* 2017; 35: 1884–90.

76. Lee WR, Dignam JJ, Amin MB et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. *J Clin Oncol* 2016; 34: 2325–32.

77. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. *Int J Radiat Oncol Biol Phys* 2007; 67: 1099–105.

78.   Loblaw A, Cheung P, D'Alimonte L et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. *Radiother Oncol* 2013; 107: 153–8.

79.   ClinicalTrials.gov. Stereotactic body radiotherapy vs intensity-modulated radiotherapy in prostate cancer [Internet]. ClinicalTrials.gov; 2018. Available at: https://clinicaltrials.gov/ct2/show/NCT02339701. Accessed 25 January 2018.

80.   Graf R, Boehmer D, Budach V, Wust P. Interfraction rotation of the prostate as evaluated by kilovoltage X-ray fiducial marker imaging in intensity-modulated radiotherapy of localized prostate cancer. *Med Dosim* 2012; 37: 396–400.

81.   Owen R, Kron T, Foroudi F, Milner A, Cox J, Duchesne G. Interfraction prostate rotation determined from in-room computerized tomography images. *Med Dosim* 2011; 36: 188–94.

82.   Li JS, Jin L, Pollack A et al. Gains from real-time tracking of prostate motion during external beam radiation therapy. *Int J Radiat Oncol Biol Phys* 2009; 75: 1613–20.

83.   Litzenberg DW, Balter JM, Hadley SW et al. Prostate intrafraction translation margins for real-time monitoring and correction strategies. *Prostate Cancer* 2012; 2012: 130579.

84.   Amro H, Hamstra DA, McShan DL et al. The dosimetric impact of prostate rotations during electromagnetically guided external-beam radiation therapy. *Int J Radiat Oncol Biol Phys* 2013; 85: 230–6.

85. Peng C, Ahunbay E, Chen G, Anderson S, Lawton C, Li XA. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy. *Int J Radiat Oncol Biol Phys* 2011; 79: 909–14.

86. Zelefsky MJ, Kollmeier M, Cox B et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2012; 84: 125–9.

87. Poon DMC, Leung C, Chu C et al. The impact of image-guided radiotherapy (IGRT) for prostate cancer (PC) on radiotherapy (RT)-related acute toxicities and prostate-specific antigen (PSA) kinetics. *J Clin Oncol* 2012; 30: e15110–e.

88. Das S, Liu T, Jani AB et al. Comparison of image-guided radiotherapy technologies for prostate cancer. *Am J Clin Oncol* 2014; 37: 616–23.

89. Wilson RR. Radiological use of fast protons. *Radiology* 1946; 47: 487–91.

90. Shipley WU, Verhey LJ, Munzenrider JE et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. *Int J Radiat Oncol Biol Phys* 1995; 32: 3–12.

91. Mendenhall NP, Li Z, Hoppe BS et al. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 2012; 82: 213–21.

92. Yonemoto LT, Slater JD, Rossi CJ, Jr. et al. Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: preliminary results of a phase I/II study. *Int J Radiat Oncol Biol Phys* 1997; 37: 21–9.

93. ClinicalTrials.gov. Proton therapy vs. IMRT for low or intermediate risk prostate cancer (PARTIQoL) [Internet]. ClinicalTrials.gov; 2018. Available at: https://clinicaltrials.gov/ct2/show/NCT01617161. Accessed 25 January 2018.

94. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. *N Engl J Med* 1997; 337: 295–300.

95. Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. *J Clin Oncol* 2003; 21: 3972–8.

96. Zapatero A, Guerrero A, Maldonado X et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. *Lancet Oncol* 2015; 16: 320–7.

97. Roach M, 3rd, DeSilvio M, Lawton C et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. *J Clin Oncol* 2003; 21: 1904–11.

98.   Lawton CA, DeSilvio M, Roach M, 3rd et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. *Int J Radiat Oncol Biol Phys* 2007; 69: 646–55.

99.   Pommier P, Chabaud S, Lagrange JL et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. *Int J Radiat Oncol Biol Phys* 2016; 96: 759–69.

100. ClinicalTrials.gov. Androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer [Internet]. ClinicalTrials.gov; 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT01368588. Accessed 25 January 2018.

101. Poon DM, Kam M, Leung CM et al. Dosimetric advantages and superior treatment delivery efficiency of RapidArc over conventional intensity-modulated radiotherapy in high-risk prostate cancer involving seminal vesicles and pelvic nodes. *Clin Oncol (R Coll Radiol)* 2013; 25: 706–12.

102. Zaorsky NG, Shaikh T, Murphy CT et al. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. *Cancer Treat Rev* 2016; 48: 50–60.

103. Yamada Y, Rogers L, Demanes DJ et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. *Brachytherapy* 2012; 11: 20–32.

104. Shen X, Keith SW, Mishra MV, Dicker AP, Showalter TN. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. *Int J Radiat Oncol Biol Phys* 2012; 83: 1154–9.

105. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. *Radiother Oncol* 2012; 103: 217–22.

106. Davis BJ, Horwitz EM, Lee WR et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. *Brachytherapy* 2012; 11: 6–19.

107. Crook JM, Gomez-Iturriaga A, Wallace K et al. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. *J Clin Oncol* 2011; 29: 362–8.

108. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. *Urol Clin North Am* 1997; 24: 395–406.

109. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA* 1999; 281: 1591–7.

110. Stephenson AJ, Scardino PT, Eastham JA et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *J Natl Cancer Inst* 2006; 98: 715–7.

111. Kristiansen A, Drevin L, Delahunt B et al. Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. *Pathology* 2017; 49: 715–20.

112. Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. *Int J Radiat Oncol Biol Phys* 1997; 37: 1043–52.

113. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. *J Urol* 1995; 154: 1818–24.

114. Valicenti RK, Thompson I, Jr., Albertsen P et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. *Int J Radiat Oncol Biol Phys* 2013; 86: 822–8.

115. Thompson IM, Jr., Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. *JAMA* 2006; 296: 2329–35.

116. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0

prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of

a randomized clinical trial. *J Urol* 2009; 181: 956–62.

117. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy:

a randomised controlled trial (EORTC trial 22911). *Lancet* 2005; 366: 572–8.

118. Bolla M, van Poppel H, Tombal B et al. Postoperative radiotherapy after radical prostatectomy

for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).

Lancet 2012; 380: 2018–27.

119. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical

prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative

undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. *J Clin Oncol* 2009; 27: 2924–30.

120. Wiegel T, Bartkowiak D, Bottke D et al. Adjuvant radiotherapy versus wait-and-see after radical

prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. *Eur Urol* 2014; 66: 243–50.

121. Hwang WL, Tendulkar RD, Niemierko A, et al. Comparison between adjuvant and early-salvage

postprostatectomy radiotherapy for prostate cancer with adverse pathological features. *JAMA Oncol*

2018; 4: e175230.

122. Hervas A, Gomez-Caamano A, Casana M et al. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database. *Clin Transl Oncol* 2018; 20: 193–200.

123. King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. *Int J Radiat Oncol Biol Phys* 2012; 84: 104–11.

124. Alongi F, Fiorino C, Cozzarini C et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. *Radiother Oncol* 2009; 93: 207–12.

125. Goenka A, Magsanoc JM, Pei X et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. *Eur Urol* 2011; 60: 1142–8.

126. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. *Int J Radiat Oncol Biol Phys* 2008; 71: 23–7.

127. Michalski JM, Lawton C, El Naqa I et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 2010; 76: 361–8.

128. Shipley WU, Seiferheld W, Lukka HR et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. *N Engl J Med* 2017; 376: 417–28.

129. ClinicalTrials.gov. Radiation therapy and androgen deprivation therapy in treating patients who have undergone surgery for prostate cancer (RADICALS) [Internet]. ClinicalTrials.gov; 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT00541047. Accessed 25 January 2018.

130. Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. *Eur Urol* 2009; 56: 609–16.

131. Warde P, Mason M, Ding K et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. *Lancet* 2011; 378: 2104–11.

132. Mason MD, Parulekar WR, Sydes MR et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. *J Clin Oncol* 2015; 33: 2143–50.

133. Jones CU, Hunt D, McGowan DG et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. *N Engl J Med* 2011; 365: 107–18.

134. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. *Eur Urol* 2000; 38: 706–13.

135. Klotz LH, Goldenberg SL, Jewett MAS et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. *J Urol* 2003; 170: 791–4.

136. Van Poppel H, De Ridder D, Elgamal AA et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. *J Urol* 1995; 154: 429–34.

137. Miyata Y, Nakamura Y, Yasuda T et al. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters. *Prostate* 2017; 77: 1408–15.

138. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. *Cochrane Database Syst Rev* 2006: Cd006019.

139. Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. *BJU Int* 2010; 105: 1074–81.

140. Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N. Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses. *Clin Oncol (R Coll Radiol)* 2014; 26: e21–46.

141. Pisansky TM, Hunt D, Gomella LG et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. *J Clin Oncol* 2015; 33: 332–9.

142. Liauw SL, Stadler WM, Correa D, Weichselbaum RR, Jani AB. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. *Int J Radiat Oncol Biol Phys* 2010; 77: 125–30.

143. Senzaki T, Fukumori T, Mori H et al. Clinical significance of neoadjuvant combined androgen blockade for more than six months in patients with localized prostate cancer treated with prostate brachytherapy. *Urol Int* 2015; 95: 457–64.

144. Bolla M, Verry C, Long JA. High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy. *Curr Opin Urol* 2013; 23: 349–54.

145. Grant JD, Litwin MS, Kwan L, Lee SP, Steinberg ML, King CR. Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study. *J Urol* 2011; 185: 1674–80.

146. Teoh JY, Chiu PK, Chan SY et al. Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer. *Aging Male* 2015; 18: 180–5.

147. Basaria S, Lieb J, 2nd, Tang AM et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. *Clin Endocrinol (Oxf)* 2002; 56: 779–86.

148. Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. *J Urol* 2004; 172: 529–32.

149. Gartrell BA, Coleman RE, Fizazi K et al. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kappaB ligand inhibitors in patients with advanced prostate cancer. *Eur Urol* 2014; 65: 278–86.

150. Voog JC, Paulus R, Shipley WU et al. Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: an analysis of RTOG 94-08. *Eur Urol* 2016; 69: 204–10.

151. Efstathiou JA, Bae K, Shipley WU et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. *Eur Urol* 2008; 54: 816-23.

152. Smith MR, O'Malley AJ, Keating NL. Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? *BJU Int* 2008; 101: 1335–6.

153. Nguyen PL, Alibhai SM, Basaria S et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. *Eur Urol* 2015; 67: 825–36.

154. Scailteux LM, Naudet F, Alimi Q, Vincendeau S, Oger E. Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: a systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. *Medicine (Baltimore)* 2016; 95: e3873.

155. Cho E, Mostaghel EA, Russell KJ et al. External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens. *Int J Radiat Oncol Biol Phys* 2015; 92: 236–43.

156. Taplin ME, Montgomery B, Logothetis CJ et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. *J Clin Oncol* 2014; 32: 3705–15.

157. Montgomery B, Tretiakova MS, Joshua AM et al. Neoadjuvant enzalutamide prior to prostatectomy. *Clin Cancer Res* 2017; 23: 2169–76.

158. Silberstein JL, Poon SA, Sjoberg DD et al. Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer. *BJU Int* 2015; 116: 50–6.

159. Thalgott M, Horn T, Heck MM et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. *J Hematol Oncol* 2014; 7: 20.

160. Fizazi K, Lesaunier F, Delva R et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. *Eur J Cancer* 2012; 48: 209–17.

161. Sandler HM, Hu C, Rosenthal SA et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). *J Clin Oncol* 2015; 33: LBA5002-LBA.

162. Cha EK, Eastham JA. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. *Urol Oncol* 2015; 33: 217–25.

163. Loblaw A, Souter LH, Canil C et al. Follow-up care for survivors of prostate cancer - clinical management: a program in evidence-based care systematic review and clinical practice guideline. *Clin Oncol (R Coll Radiol)* 2017; 29: 711–7.

164. Matsumoto K, Komatsuda A, Yanai Y et al. Determining when to stop prostate specific antigen monitoring after radical prostatectomy: the role of ultrasensitive prostate specific antigen. *J Urol* 2017; 197: 655–61.

165. Roach M, 3rd, Hanks G, Thames H, Jr. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int J Radiat Oncol Biol Phys* 2006; 65: 965–74.

166. Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. *J Clin Oncol* 2007; 25: 2035–41.

167. Cher ML, Bianco FJ, Jr., Lam JS et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. *J Urol* 1998; 160: 1387–91.

168. Kane CJ, Amling CL, Johnstone PA et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. *Urology* 2003; 61: 607–11.

169. James ND, Spears MR, Clarke NW et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. *JAMA Oncol* 2016; 2: 348–57.

170. Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. *J Natl Cancer Inst* 2015; 107.

171. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. *N Engl J Med* 1999; 341: 1781–8.

172. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. *J Clin Oncol* 2009; 27: 100–5.

173. Schroder FH, Kurth KH, Fossa SD et al. Early versus delayed endocrine treatment of T2–T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). *Eur Urol* 2009; 55: 14–22.

174. Abdollah F, Karnes RJ, Suardi N et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. *J Clin Oncol* 2014; 32: 3939–47.

Table 1 ISUP grades relative to Gleason scores [32].

| Gleason score	ISUP grade
2–6	1
7 (3+4)	2
7 (4+3)	3
8 (4+4 or 3+5 or 5+3)	4
9–10	5

ISUP, International Society of Urological Pathology.

Table 2 D'Amico risk stratification of localised prostate cancer [40].

Low risk	Intermediate risk	High risk
PSA < 10 ng/mL and	PSA = 10 to 20 ng/mL or	PSA > 20 ng/mL or
Gleason score < 7 and	Gleason score = 7 or	Gleason score > 7 or
cT1–2a	cT2b	≥ cT2c

PSA, prostate-specific antigen.

Figure 1 Diagnostic work-up and staging for suspicious localised PCa.

"f/t PSA or PHI may aid counselling of the decision on whether to do a prostate biopsy.
†TRUS-guided biopsy with 10–12 cores is recommended.
‡mpMRI or combination of systematic and MRI-targeted biopsies (either with cognitive guidance or mpMRI/ultrasound fusion) can be offered.

CT, computed tomography; f/t PSA, free/total PSA ratio; ISUP, International Society of Urological Pathology; mpMRI, multiparametric magnetic resonance imaging; PCa, prostate cancer; PET, positron emission tomography; PHI, prostate health index; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; TRUS, transrectal ultrasound.

Figure 2 Localised PCa treatment algorithm.

*Offer to patients not eligible for local curative treatment (e.g. poor premorbid status) and those with a short life expectancy (< 10 years).

†Offer to patients with a low risk of extracapsular disease (based on nomograms).

‡Offer when the estimated risk of lymph node metastasis is > 5% based on nomograms.

§With consideration of the patient's history, functional status, values and preferences, and his tolerance for the potential toxicities and impact on quality of life due to RT.

ADT, androgen deprivation therapy; EBRT, external beam radiation therapy; ePLND, extended pelvic lymph node dissection; PCa, prostate cancer; PSA, prostate-specific antigen; RP, radical prostatectomy; RT, radiation therapy.